1. Is Unichem Laboratories Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Unichem Laboratories Ltd is a below average quality company.
2. Is Unichem Laboratories Ltd undervalued or overvalued?
The key valuation ratios of Unichem Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Unichem Laboratories Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Unichem Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||15.9%||13.7%||7.2%||11.4%||11.2%||130.8%||-0.4%||-3.5%||1.8%||-2.4%||-|
|Value Creation Index ⓘ||0.1||-0.0||-0.5||-0.2||-0.2||8.3||-1.0||-1.3||-0.9||-1.2||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||3.9%||4.5%||11.9%||16.2%||-13.2%||-20.8%||-7.3%||24.3%||-16.1%||-|
|Adj EPS ⓘ||13.8||12.9||7.1||12.2||13.2||361.6||-1.6||-13.6||6.5||-9.5||-14.9|
|YoY Gr. Rt. %||-||-6.7%||-44.7%||71.3%||8.4%||2631.4%||-100.4%||NA||NA||-244.9%||-|
|BVPS (₹) ⓘ||89.8||99.9||104.3||112.9||124.3||392.6||387.6||375.3||382||378||367|
|Adj Net Profit ⓘ||125||117||64.8||111||120||2,544||-11.2||-95.5||45.9||-66.5||-105|
|Cash Flow from Ops. ⓘ||180||86.9||88||117||141||-66.3||-251||-41.8||-32.6||-158||-|
|Debt/CF from Ops. ⓘ||0||0||0||0.1||0||-0||0||-0.4||0||-0.8||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-195.9%||-193.5%||NA||-244.9%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||16.2||13.6||7||11.2||11.2||130.7||-0.4||-3.6||1.7||-2.5||-4|
|Op. Profit Mgn % ⓘ||18.3||17.5||9.7||13.5||13.6||2.2||-4.7||-9.9||8.5||-4||-4.5|
|Net Profit Mgn % ⓘ||12.4||11.2||5.9||9.1||8.5||206.6||-1.2||-10.6||4.1||-7.1||-10.1|
|Debt to Equity ⓘ||0||0||0||0||0||0||0||0||0||0.1||0|
|Working Cap Days ⓘ||150||171||183||173||171||200||296||385||344||445||432|
|Cash Conv. Cycle ⓘ||49||59||71||63||-9||28||113||169||154||245||339|
No data to display
Return on Equity is Poor
Sales growth has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at 7.54%
|TTM EPS (₹)||-14.9||-5.2|
|TTM Sales (₹ Cr.)||1,036||1,320|
|BVPS (₹.) ⓘ||367||361.5|
|Reserves (₹ Cr.) ⓘ||2,570||2,531|
|From the Market|
|52 Week Low / High (₹)||226.00 / 467.00|
|All Time Low / High (₹)||1.50 / 467.00|
|Market Cap (₹ Cr.)||2,378|
|Equity (₹ Cr.)||14.1|
|Face Value (₹)||2|
|Industry PE ⓘ||35.8|
Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business.
The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.
Headquartered in Mumbai, the company operates at five manufacturing locations in Roha (Maharashtra), Goa,
The companyâ€™s manufacturing facilities have received approval from various international agencies namely UK MHRA, MCC (
Unichem also operates a research and development facility located at Jogeshwari (Mumbai). This facility conducts research in area of Novel Drug Delivery Systems (NDDS) and develops non-infringing routes for the manufacture of products directed at the regulated markets.
1944- Unichem was commissioned by Late Amrut Mody.
1952- The company forayed into exporting activities.
1953- Unichem entered into hormonal products segment. The same year it launched UNIPROGESTIN.
1962- The company collaborated with foreign entity UCB for bulk-drugs. It set up its first formulation plant at Jogeshwari. The company got listed at Bombay Stock Exchange. Unichem launched OESTROGEN and Progestin.
1963- The company entered co-marketing of formulations tie up with Uni Sankyo.
1968- Unichem set up a formulation plant at
1970- As part of back integration strategy, the company commissioned manufacturing of Anti-TB Drugs.
1972- As an acknowledgement for Late Amrut Modyâ€™s pioneering effort in Indian pharma industry, he was awarded Padma Bhushan.
1973- Unichem's research laboratory was recognised for Phd work by
1976- The company set up a fine chemicals unit at Roha.
1978- Unichem commissioned its Roha bulk drug plant.
1979- The company received its first clearance from drug authorities for NEFEDIFINE.
1983- Unichem received the USFDA approval for hydrochlorothiazide manufactured at the Jogeshwari plant. The company introduced Anti-TB - Isoniazid, Rifampicin in white tablet form for the first time in
1984- UNISEARCH was established in collaboration with Upjohn. The company forayed anti-biotic segment and launched Ampoxin (Ampicillin and Cloxacillin combination).
1987- The company entered the animal health care business.
1994-1999- Unichem underwent thorough restructuring and transformation in line with future growth strategies.
1996- Two companies namely Unichem Exports and Unisearch was merged with Unichem Laboratories.
1997- The companyâ€™s formulation plant located at
1998- The companyâ€™s formulations plant located at Baddi was fully operational.
1997-2000- The company implemented BaaN ERP.
1999- Unichem set up a modern multipurpose bulk drug plant located at Roha. Molecular generics division was launched.
2000- The drug major received South African Health Authority and UK MCA (MHRA) certifications for
2001- Unichem set up new research and development centre at Mumbai. The same year it also set up New Biosciences R&D Centre located at
2002- It formed a joint venture in
2002-2003- The company divested its animal healthcare division. It established subsidiaries in
2004- Unichem conducted restructuring of Unisearch and launched of Unisearch CD Division.
2005- The company set up of new pharma technology development center located at
2006- The company received USFDA certification for the Goa Plant. It launched specialities division. In the same year it acquired 100% stake in Niche Generics,
2007- Unikare division launched that catered to Dermatology and Allied therapies segment.
Unichem will continue to work on the therapeutic segments and will develop cost effective processes for the existing molecules. It will also focus on develop new drug delivery systems and new products for international business.